Financial Data and Key Metrics Changes - The company reported a market cap of approximately $12 million, with stock trading around $0.25 to $0.30 per share [30][53] - The company anticipates collecting at least $50 million net from Crown Medical's initiatives, which could significantly impact its financial structure [15][46] Business Line Data and Key Metrics Changes - Crown Medical Collections is actively pursuing approximately $150 million in uncollected COVID testing reimbursements from insurance companies, with a focus on underpaid claims [9][10] - The B-Smart esophageal cancer test is positioned as a highly valuable diagnostic tool, with a potential market size of $7 billion to $14 billion if reimbursement rates are between $1,000 and $2,000 per test [20][21] - Nebula Genomics has transitioned to a direct-to-consumer model, with a high profit margin on subscription renewals, indicating a shift towards profitability [24][25] Market Data and Key Metrics Changes - The company is experiencing pressure from short sellers, which is affecting stock performance, but management believes that cash flow from Crown Medical will change this dynamic [27][54] - The overall market for crypto treasury stocks is currently unfavorable, but management sees potential for long-term growth in this area [6][37] Company Strategy and Development Direction - The company is focused on strategic initiatives that recognize underlying value, including potential partnerships and M&A opportunities [4][35] - Management emphasizes the importance of NASDAQ compliance and shareholder voting to support strategic initiatives [35][50] - The company aims to maintain a lean operational structure while focusing on core businesses, particularly Crown Medical and the B-Smart test [26][59] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the challenges faced in the past year but expresses optimism about upcoming cash flow from Crown Medical and the potential for significant growth [27][55] - The company is exploring various funding options to support operations until cash flow stabilizes [43][44] Other Important Information - The company has undergone significant restructuring, including the sale of its Farm Labs manufacturing facility and the shutdown of its Nebula Genomics laboratory [26] - Management has deferred salaries to support the company financially, indicating a commitment to the company's success [29][30] Q&A Session Summary Question: Clarification on potential major deals - Management is exploring multiple strategic deals, including a reverse crypto strategy and other initiatives that could enhance shareholder value [37] Question: Impact of reverse stock split on stock price - Management believes that a reverse stock split could lead to an increase in stock price, especially if the company maintains its NASDAQ compliance [39][41] Question: Plans for employee compensation with limited cash - Management reassured that they have multiple funding options available and are confident in the company's underlying asset value [43][44] Question: Timeline for Crown Medical collections - Management expects to see significant cash flow from Crown Medical in the coming months, which will positively impact the company's financial situation [55] Question: Strategy for B-Smart development - Management plans to adopt a grassroots approach for the B-Smart test, seeking partnerships and leveraging existing relationships to minimize costs [56][59]

Financial Data and Key Metrics Changes - The company has a market cap of approximately $12 million, with stock trading around $0.25 to $0.30 per share, indicating a significant decline from previous levels [30][53]. - The company is estimating to collect at least $50 million net from Crown Medical's initiatives, which is a significant potential cash influx [15][46]. Business Line Data and Key Metrics Changes - Crown Medical Collections is actively pursuing approximately $150 million in uncollected COVID testing claims, with a focus on underpaid claims from insurance companies [9][10]. - The BE-Smart Esophageal Cancer Test is positioned as a leading diagnostic tool for esophageal cancer, with a potential market value of $7 billion to $14 billion if reimbursement rates are between $1,000 and $2,000 per test [20][21]. Market Data and Key Metrics Changes - The company has identified a growing market for its esophageal cancer test, with 7 million endoscopies performed annually in the U.S. for high-risk patients, suggesting a substantial opportunity for commercialization [19][20]. - The company has a strong database from Nebula Genomics, which is considered more valuable than its current market cap, indicating significant underlying asset value [25]. Company Strategy and Development Direction - The company is focusing on strategic initiatives that could recognize significant underlying value, including a potential reverse stock split and a crypto treasury strategy [5][35]. - The management is committed to maintaining Nasdaq compliance to facilitate potential deals that could enhance shareholder value [35][49]. Management's Comments on Operating Environment and Future Outlook - Management acknowledges the challenges faced in the past year but expresses optimism about upcoming cash flow from Crown Medical, which is expected to transform the company's financial position [27][55]. - The management believes that the stock price will improve significantly once cash flow from Crown Medical starts to materialize, and they are exploring various funding options to support operations until then [43][46]. Other Important Information - The company has undergone significant restructuring, including the sale of its Pharmaloz manufacturing facility and the shutdown of its Nebula Genomics laboratory, to streamline operations and reduce overhead [26]. - Management emphasizes the importance of shareholder voting on proxies to support strategic initiatives and ensure the company's future [4][35]. Q&A Session Summary Question: Can you clarify the potential major deals being worked on? - Management is exploring multiple deals, including a reverse crypto strategy and other strategic initiatives that could be accretive for shareholders [37]. Question: Is it possible that the stock price will go up or down after a reverse stock split? - Management indicates that a reverse stock split could lead to an increase in stock price, especially if the company maintains its underlying asset value [39]. Question: Does the crypto treasury strategy remain part of the company's vision? - Management confirms that the crypto treasury strategy is still on the table, but they are also pursuing other potentially accretive deals [42]. Question: How will the company pay employees and board going forward with limited cash? - Management states that they have multiple investors willing to support the company with various funding options, ensuring operational continuity [43]. Question: When will the company stop mentioning the possibility of collecting $25 million in accounts receivables? - Management believes that significant cash flow will start coming in soon, leading to a different financial situation for the company [55]. Question: Is it realistic to use a go-it-alone strategy for BE-Smart? - Management is considering partnerships for the BE-Smart test but aims to minimize expenses and leverage existing resources as cash flow improves [56][59].

Financial Data and Key Metrics Changes - The company has a market cap of approximately $12 million, with stock trading around $0.25 to $0.30 per share, reflecting a significant decline from previous levels [32][56]. - The company is estimating to collect at least $50 million net from Crown Medical's initiatives, which is expected to significantly improve the financial structure [17][18]. Business Line Data and Key Metrics Changes - Crown Medical Collections has been appointed as special counsel to pursue approximately $150 million in uncollected COVID testing claims, with expectations of settlements starting soon [10][15]. - The B-Smart esophageal cancer test is positioned as a potentially multi-billion dollar market opportunity, with a target market estimated between $7 billion and $14 billion [21][22]. Market Data and Key Metrics Changes - The company is experiencing a disconnect between its market cap and the underlying asset value, particularly with the anticipated cash inflow from Crown Medical [7][17]. - The company has not utilized its ATM (at-the-market) facility yet, indicating a cautious approach to financing amid current market conditions [18]. Company Strategy and Development Direction - The company is focusing on strategic initiatives that could recognize significant underlying value, including a potential reverse stock split and a crypto treasury strategy [5][37]. - The management is committed to maintaining NASDAQ compliance to facilitate potential strategic deals and enhance shareholder value [37][52]. Management's Comments on Operating Environment and Future Outlook - Management acknowledges the current challenges but expresses optimism about upcoming cash flows from Crown Medical, which could transform the company's financial position [28][59]. - The management emphasizes the importance of shareholder voting to support strategic initiatives and maintain compliance with NASDAQ [38][52]. Other Important Information - The company has undergone significant restructuring, including the sale of its Farm Labs manufacturing facility and the shutdown of its Nebula Genomics laboratory, to streamline operations and reduce overhead [27]. - Management has deferred salaries to support the company financially, indicating a commitment to the company's success [31]. Q&A Session Summary Question: Clarification on potential major deals - Management is exploring multiple strategic deals, including a reverse crypto strategy and other initiatives that could enhance shareholder value [40]. Question: Impact of reverse stock split on stock price - Management believes that a reverse stock split could potentially lead to an increase in stock price, especially if the company maintains its underlying asset value [42][44]. Question: Plans for employee compensation amid cash constraints - Management reassures that there are multiple funding options available, including debt, to support operations and employee compensation [46]. Question: Strategy for B-Smart esophageal cancer test funding - Management intends to leverage cash flow from Crown Medical to fund the B-Smart initiative, with potential for joint ventures to enhance value [60][62]. Question: Addressing ongoing stock price decline - Management attributes the stock price decline to market conditions and short selling, expressing confidence that cash flow from Crown Medical will drive stock price recovery [58].